BioVaxys And SpayVac For Wildlife, Inc. Expand License Agreement Into Commercial Aquaculture

VANCOUVER and MADISON — BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. jointly announce an expansion of the Fields of Use in the current License Agreement to include commercial aquaculture, plus the farm-raised fish market. With this expansion in the Fields of Use, SpayVac-for-Wildlife’s markets now include its no-booster fertility-control vaccines for aquaculture as well as overabundant feral/wild/invasive animals, and select production and companion animals, which increases SpayVac’s global revenue potential.

The global market for farm-raised Atlantic salmon and rainbow trout represents a significant commercial opportunity for SpayVac. According to Seafish, a UK-based public body supporting the aquaculture industry, the annual harvest of these two species totals approximately 3.28 million metric tons, equating to an estimated 800 million individual fish. SpayVac-for-Wildlife CEO Thomas D’Orazio says “This presents a substantial addressable market for SpayVac’s contraceptive vaccines, which are being developed as an alternative to triploidy—a form of genetic manipulation commonly used in aquaculture to induce sterility. With only a single dose required, SpayVac’s immunocontraceptive approach offers producers a scalable and cost-effective solution for reproductive control in farmed fish, opening the door to meaningful vaccine sales across the global aquaculture sector.”

Initial proof-of-concept trials in aquaculture are well underway, and the program has now advanced to the second phase of development, focusing on optimizing the timing of injection within the fish’s life cycle.

SpayVac says their vaccines render animals infertile with a single-dose product. At the core of SpayVac’s technology is a patented liposome-based delivery platform developed by BioVaxys and licensed to SpayVac, designed to create long-lasting, targeted immune responses.

SpayVac has reportedly initiated the submission process to secure regulatory approval for its first product targeting feral horses and free-ranging deer populations, with the U.S. Bureau of Land Management (BLM) serving a potential lead customer to manage free-roaming feral horse and burro populations.

“We are extremely pleased and excited with the progress of SpayVac-for-Wildlife,” says BioVaxys President and Chief Operating Officer Kenneth Kovan. “Based on the superior profile of SpayVac vaccines and the U.S. market potential with feral horses and deer, we are anticipating a healthy revenue stream from royalties on sales of SpayVac. With huge global markets for horses and deer, such as Australia, and the expansion into commercial aquaculture including the farm-raised fish market, SpayVac is positioned to become a significant player in the animal health field.”